Displaying drugs 2201 - 2225 of 3199 in total
7,9-Dimethylguanine
Experimental
Matched Iupac: … (2R,6S)-2-amino-6-hydroxy-7,9-dimethyl-2,3,6,9-tetrahydro-1H-purin-7-ium …
Coumermycin A1
Experimental
Matched Iupac: … (3S,4R,5S,6S)-5-hydroxy-6-[(4-hydroxy-3-{5-[(4-hydroxy-7-{[(2S,3S,4R,5S)-3-hydroxy-5-methoxy-6,6-dimethyl ... oxy}-8-methyl-2-oxo-2H-chromen-3-yl)carbamoyl]-4-methyl-1H-pyrrole-3-amido}-8-methyl-2-oxo-2H-chromen-7- …
Chrysin
Experimental
Larcaviximab
Investigational
8-Aminotheophylline
Experimental
Lumichrome
Experimental
Lumiflavin
Experimental
Tilorone
Investigational
7,8-Dihydroneopterin
Experimental
4,7-Dioxosebacic Acid
Experimental
N7-Methyl-Formycin A
Experimental
Matched Iupac: … (2R,3S,4R,5S)-2-(hydroxymethyl)-5-[7-(methylamino)-2H-pyrazolo[4,3-d]pyrimidin-3-yl]oxolane-3,4-diol …
Oxypurinol
Oxypurinol, an inhibitor of xanthine oxidase, is a metabolite of allopurinol.
Investigational
Nisevokitug
Nisevokitug is a monoclonal antibody targeted against transforming growth factor beta (TGFβ) under investigation in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis Patients).
Investigational
Seletracetam
Seletracetam is a pyrrolidone derivative and with a structural similarity to newer generation antiepileptic drug levetiracetam. It binds to the same target as levetiracetam but with higher affinity and has shown potent seizure suppression in models of acquired and genetic epilepsy with high CNS tolerability. It is predicted to have...
Investigational
STRO-001
Investigational
Morin
Experimental
Chrysoeriol
Investigational
Displaying drugs 2201 - 2225 of 3199 in total